FY 2026 1H Financial Results Presentation

from the beginning

FY 2026 1H Financial Results Presentation

• AGENDA

• The Evolution of PeptiDream

• Clinical Pipeline Expansion - Driving Value Creation

• Our 5 Core Focus Areas - A Wealth of Opportunities

• Our Five Core Focus Areas - Asset Creation Engine

• FY2026 1H Highlights - 6 Programs Entered Clinical Pipeline

• Pipeline Overview: Radiopharmaceuticals

• Pipeline Overview: Peptide (non-RI)

• Major Clinical Pipeline Advances in FY2026 1H

• PDRadiopharma: Commercial Strength into Future Product Value

• Commercial Engine: PET Revenue Grew 30% YoY

• Advancing Late-Stage Assets to Potential Product Revenue in Japan

• Radiopharmaceuticals Recognized in Japan’s National Policy

• Overview of FY2026 1H Consolidated Results

• Reaffirmed FY 2026 Financial Guidance

• Strong Cash Position to Execute Strategy

• New Leadership Team from July 1

• Welcoming New EVPs

• Sustainability as a Foundation for Next-Generation Medicines

Appendix

• PeptiDream-Mission, Vision, Values

• PeptiDream Overview

• PeptiDream - The Epicenter of Peptide Drug Discovery

• PDRadiopharma: Current Key Products Overview

• Total Solution Provider in Japan Radiopharmaceuticals Field

• Consolidated/Equity Method Applied Companies

• Major Progress of PeptiDream’s Equity Holdings

• External Directors at PeptiDream

• Analyst Coverage

• Forward-Looking Statements

@